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MEETING REPORT
The Third International Inflammatory Breast
Cancer Conference
Kenneth L van Golen1,2 and Massimo Cristofanilli3*
Abstract
Inflammatory breast cancer (IBC) is the most aggressive
and deadly form of breast cancer. Disease-specific
research and conferences have been organized since
2008 with the intent to bring together experts in
various disciplines. This report focus on the Third
International IBC Conference held in Philadelphia on
December 2012.
Meeting goals
The Third International Inflammatory Breast Cancer Con-
ference, held on 1–2 December 2012 in Philadelphia, was
an opportunity to gather physicians and scientists dedi-
cated to the study and treatment of patients affected by
this aggressive form of breast cancer. The meeting objec-
tives included an education on the peculiar clinical and
molecular aspects of inflammatory breast cancer (IBC)
and discussion of the latest developments in clinical care
and translational research. IBC is arguably the most ag-
gressive form of breast cancer and is often misdiagnosed
as an infection [1]. The disease is a phenotypically distinct
and unique disease compared to other forms of breast
cancer [2]. The meeting was attended by 137 participants
representing eight countries.
Meeting sessions
The opening session began with welcoming remarks and
an introduction about the importance of the conference in
providing guidelines regarding the course of future re-
search, including the investigation of novel treatments
with potential impact on patients’ outcome. Distinguished
speakers Margaret Foti (American Association for Cancer
Research), Francis Visco (National Breast Cancer Coalition),
Elaine Grobman (Philadelphia Affiliate of Susan G Komen
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for the Cure) and Senator Timothy Z Jennings of the New
Mexico State Senate took part in the opening session.
The plenary lecture was delivered by Chi Van Dang
(Abramson Cancer Center, University of Pennsylvania,
USA) and provided an overview of the evolving concepts
regarding the role of the myc oncogene in regulating
tumor metabolism [3]. The first scientific session was ded-
icated to the epidemiological aspects of IBC. Paul Levine
(George Washington University School of Medicine,
Washington, DC, USA) gave an overview of what is
known about IBC epidemiology, including a discussion of
recently identified clusters of new cases in various parts of
the United States, strongly suggesting a potential environ-
mental factor in the etiology of the disease [4]. The session
included the presentation of two original studies selected
from among the submitted abstracts for their original con-
tribution. Hugo Arias-Pulido (University of New Mexico
Cancer Center, USA) presented a retrospective study
conducted in collaboration with investigators in Algeria,
North Africa, demonstrating the detection of mouse mam-
mary tumor virus-like sequences in mastectomy speci-
mens from patients with IBC. Arias-Pulido’s work suggests
the possibility of a potential link between the disease and
exposure to mouse mammary tumor virus, which requires
further confirmatory investigation. The second study was
presented by Catherine Schairer (The National Cancer
Institute, Bethesda, Maryland, USA) and focused on risk
factors pertaining to IBC and advanced breast cancers [5].
Schairer’s study included a comparison of a very large co-
hort of IBC and non-IBC patients and looked at factors
that included family history, body mass index, education
and age at first birth. The results of the study demonstrate
varying risk factors that suggest a distinct etiology of IBC.
The opening day ended with an advocate session and
presentations by representatives of the Inflammatory
Breast Cancer Foundation, The IBC Network, the Inflam-
matory Breast Cancer Research Foundation and the Triple
Negative Breast Cancer Foundation.
The second day opened with a session dedicated to
breaking news in IBC research update. The opening
© BioMed Central Ltd.




lecture was given by Patricia S Steeg (The National Cancer
Institute, Bethesda, Maryland, USA). Steeg discussed her
current work in understanding brain metastasis and the
development of potential targeted therapies for this devas-
tating condition [6,7]. Subsequently, there were original
contributions on current novel studies of new targets in
IBC. Zhaomei Mu (Fox Chase Cancer Center, Philadelphia,
PA, USA) presented a preclinical study using the epidermal
growth factor (EGF) family inhibitor AZD8931 against
HER2-expressing IBC cells (SUM190) and EGF receptor-
positive cells (SUM149) and the recently described
FC-IBC-02. Naoto Ueno (MD Anderson Cancer Center,
Houston, TX, USA) described his laboratory’s work on the
promotion of epithelial-mesenchymal and stem cell-like
populations in EGF receptor-overexpressing IBC by
COX-2 [8], indicating a potential therapeutic role for in-
hibitors of this pathway. Subsequently, Fredika Robertson
(MD Anderson Cancer Center) described her work on
anaplastic lymphoma kinase protein expression (without
associated rearrangement) promoting the formation of
intralymphatic tumor emboli [9]. The therapeutic targeting
of platelet-derived growth factor receptor (PDGFR)α was
the topic of Madhura Jogleka’s presentation (University of
Delaware, USA). Jogleka proposed this new modeling of
lymphatic flow for the study of the migration of SUM149
identified PDGFRα overexpression as a critical pathway for
disease progression and metastases in IBC [10]. Finally,
Bedrich Eckhardt (MD Anderson Cancer Center) pre-
sented novel work using adeno-associated virus and M13
phage that display tumor-homing peptides to target IBC.
A concurrent session for nurses, allied health professionals
and advocates was held and featured an overview of IBC
past, present and future by Pam Alizadeh (MD Anderson
Cancer Center). A panel discussion on the role of advo-
cates in IBC research and education closed out the session.
The third session focused on evolving treatments for
IBC, from bench to bedside. The opening plenary lecture
was presented by Neil Spector (Duke Cancer Institute,
Durham, NC, USA) and focused on evolving HER2-
targeted therapies in breast cancer with an emphasis on
how they can be applied to IBC, which tends to be a
Her2 expressing cancer [11]. Four abstracts were se-
lected for oral presentation in this session. The first was
presented by Hiroko Masuda (MD Anderson Cancer
Center) and described a study determining the efficacy
of neoadjuvant systemic therapy in estrogen receptor-
positive versus HER2-positive IBCs. This study used a
large cohort of 545 patients and determined that IBC
patients that are estrogen receptor-negative and HER2-
positive benefited from neoadjuvant systemic therapy.
Rachel Atkinson (MD Anderson Cancer Center) pre-
sented an elegant description of the epidemiological risk
factors and normal breast tissue markers involved in
IBC. She described a novel stem cell-like pattern unique
to IBC, which was identified in all samples from 160
patients. The third abstract was presented by Fredika
Robertson and represented an expansion of her work
with anaplastic lymphoma kinase in IBC. In this presen-
tation she demonstrated the prevalence of anaplastic
lymphoma kinase pathway activation, which is associated
with genetic changes in the gene. The final presentation
was by R Katherine Alpaugh (Fox Chase Cancer Center)
and described differences in genetic mutations between dif-
ferent tissue sources from the same patient. Next-generation
sequencing was performed for 182 cancer-related genes
on multiple tissue sources from 32 patients. This work
concluded that sequencing to identify therapeutic targets
should represent current disease [12,13].
The fourth educational session addressed unanswered
questions on loco regional therapies. The plenary lecture
was given by Wendy Woodward (MD Anderson Cancer
Center) and addressed some of the evolving loco regional
radiation therapies for IBC. One abstract was chosen for
presentation in this session. H Carisa Le-Petross (MD
Anderson Cancer Center, Houston, Texas, USA) discussed
assessment of residual disease in IBC patients who re-
ceived neoadjuvant chemotherapy, using mammography,
ultrasound, and magnetic resonance imaging. The work
determined that both ultrasound and magnetic resonance
imaging are effective in determining residual disease in
patients [14,15].
The final session covered the handling, analysis and
imaging of tissue in the laboratory. It opened with an in-
vited lecture from Emanuel F Petricoin (George Mason
University, Fairfax, VA, USA) on the use of protein micro-
arrays for molecular diagnostics and therapeutic targeting
[16]. Francois-Clement Bidard (Institut Curie, Paris,
France) presented findings from the BEVERLY 01 and 02
trials focusing on the detection of circulating tumor cells
and circulating endothelial cells in IBC patients [17].
These patients received neoadjuvant chemotherapy com-
bined with bevacizumab and trastuzumab. Analysis found
that circulating tumor cell and circulating endothelial cell
levels dropped from baseline in both studies as a result of
treatment.
The conference ended with a round table discussion in-
cluding all of the conference participants. The discussion
highlighted educational and research priorities in IBC.
Specific priorities include rigorous epidemiological studies
with a focus on environmental factors and further expan-
sion of preclinical models supporting the rational develop-
ment of dedicated clinical trials.
Conclusion
The intent of the third international IBC conference was
to focus on new and upcoming areas of research, diag-
nosis and treatment in IBC. Several new areas of re-
search focused on identifying novel molecular targets
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were presented, as well as new diagnostic methods and
the results of new treatment modalities. Thus, this con-
ference highlighted the significant progress that has been
made in the IBC field over the past 2 years.
Abbreviations
EGF: Epidermal growth factor; IBC: Inflammatory breast cancer;
PDGFR: Platelet-derived growth factor receptor.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Biological Sciences, 320 Wolf Hall, The Center for
Translational Cancer Research, The University of Delaware, Newark, DE 19716,
USA. 2The Helen F Graham Cancer Center, 4701 Ogletown Stanton Road,
Newark, DE 19713, USA. 3Department of Medical Oncology, Thomas
Jefferson University, Kimmel Cancer Center, 1025 Walnut St-Suite 700,
Philadelphia, PA 19107, USA.
Published:
References
1. Dushkin H, Cristofanilli M: Inflammatory breast cancer. J Natl Compr Canc
Netw 2011, 9:233–240.
2. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S,
Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward
WA, Buchholz T, Lucci A, Ueno NT, Cristofanilli M: Inflammatory breast
cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010,
60:351–375.
3. Dang CV: MYC on the path to cancer. Cell 2012, 149:22–35.
4. Duke TJ, Jahed NC, Veneroso CC, Da Roza R, Johnson O, Hoffman D, Barsky
SH, Levine PH: A cluster of inflammatory breast cancer (IBC) in an office
setting: additional evidence of the importance of environmental factors
in IBC etiology. Oncol Rep 2010, 24:1277–1284.
5. Schlichting JA, Soliman AS, Schairer C, Schottenfeld D, Merajver SD:
Inflammatory and non-inflammatory breast cancer survival by
socioeconomic position in the Surveillance, Epidemiology, and End
Results database, 1990–2008. Breast Cancer Res Treat 2012, 134:1257–1268.
6. Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price
JE: The role of MMP-1 in breast cancer growth and metastasis to the
brain in a xenograft model. BMC Cancer 2012, 12:583.
7. Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM,
Silberman S, Palmieri D, Steeg PS: TPI-287, a new taxane family member,
reduces the brain metastatic colonization of breast cancer cells. Mol
Cancer Ther 2012, 11:1959–1967.
8. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P,
Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT: Epidermal growth
factor receptor tyrosine kinase inhibitor reverses mesenchymal to
epithelial phenotype and inhibits metastasis in inflammatory breast
cancer. Clin Cancer Res 2009, 15:6639–6648.
9. Robertson FM, Petricoin, Iii EF, Van Laere SJ, Bertucci F, Chu K, Fernandez SV,
Mu Z, Alpaugh K, Pei J, Circo R, Wulfkuhlse J, Ye Z, Boley KM, Liu H, Moraes
R, Zhang X, Demaria R, Barsk SH, Sun G, Christofanilli M: Amplification of
anaplastic lymphoma kinase (ALK) as a common genetic alteration in
inflammatory breast cancer. Springerplus 2013, 2:497.
10. Lehman HL, Dashner EJ, Lucey M, Vermeulen P, Dirix L, Van Laere S, van
Golen KL: Modeling and characterization of inflammatory breast cancer
emboli grown in vitro. Int J Cancer 2013, 132:2283–2294.
11. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P,
Lombardi DP, Ben Ahmed S, Citrin DL, DeSilvio ML, Harris J, Westlund RE,
Salazar V, Zaks TZ, Spector NL: Phase II study of predictive biomarker
profiles for response targeting human epidermal growth factor receptor
2 (HER-2) in advanced inflammatory breast cancer with lapatinib
monotherapy. J Clin Oncol 2008, 26:1066–1072.
12. Cristofanilli M, Alpaugh KR, Ross J, Binghman C, Wu H, Stephens P, Lipson D,
Palmer G: Next generation genomic sequencing (NGS) identifies
molecular targets in inflammatory breast cancer (IBC). Cancer Res 2012,
72. abstract PD5-01(124s).
13. Alpaugh RK, Bingham C, Fittipaldi P, Banzi M, Palmber G, Christofanilli M:
What is the appropriate sample (s) on which to perform sequencing for
mutational analysis to guide the selection of targeted therapy? Cancer
Res 2012, 72. abstract PD5-03(125s).
14. Le-Petross HT, Cristofanilli M, Carkaci S, Krishnamurthy S, Jackson EF, Harrell
RK, Reed BJ, Yang WT: MRI features of inflammatory breast cancer. AJR
Am J Roentgenol 2011, 197:W769–W776.
15. Le-Petross H, Uppendahl L, Stafford J: Sonographic features of
inflammatory breast cancer. Semin Roentgenol 2011, 46:275–279.
16. Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ: Reverse
phase protein microarrays and their utility in drug development.
Methods Mol Biol 2013, 986:187–214.
17. Pierga JY, Petit T, Delozier T, Ferrero JM, Campone M, Gligorov J, Lerebours
F, Roché H, Bachelot T, Charafe-Jauffret E, Pavlyuk M, Kraemer S, Bidard FC,
Viens P: Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for
primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-
label, single-arm phase 2 study. Lancet Oncol 2012, 13:375–384.
Cite this article as: van Golen and Cristofanilli: The Third International
Inflammatory Breast Cancer Conference. Breast Cancer Research
van Golen and Cristofanilli Breast Cancer Research Page 3 of 3
05 Nov 2013
10.1186/bcr3571
2013, 15:318
2013, 15:318
http://breast-cancer-research.com/content/15/6/318
